Tradename | Company | Number | Date | Products |
---|---|---|---|---|
TRIUMEQ | ViiV Healthcare | N-205551 RX | 2014-08-22 | 1 products, RLD, RS |
TRIUMEQ PD | ViiV Healthcare | N-215413 RX | 2022-03-30 | 1 products, RLD, RS |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
TRIZIVIR | ViiV Healthcare | N-021205 DISCN | 2000-11-14 | 1 products, RLD |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
DOVATO | ViiV Healthcare | N-211994 RX | 2019-04-08 | 1 products, RLD, RS |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
DELSTRIGO | Merck Sharp & Dohme | N-210807 RX | 2018-08-30 | 1 products, RLD, RS |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
EPIVIR-HBV | GSK | N-021003 RX | 1998-12-08 | 1 products, RLD, RS |
EPIVIR-HBV | GSK | N-021004 RX | 1998-12-08 | 1 products, RLD, RS |
EPIVIR | ViiV Healthcare | N-020564 RX | 1995-11-17 | 2 products, RLD |
EPIVIR | ViiV Healthcare | N-020596 RX | 1995-11-17 | 1 products, RLD, RS |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
LAMIVUDINE, NEVIRAPINE AND ZIDOVUDINE | Micro Laboratories | N-205626 DISCN | 2018-08-13 | 1 products, RLD |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
DUTREBIS | Merck Sharp & Dohme | N-206510 DISCN | 2015-02-06 | 1 products |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
LAMIVUDINE AND ZIDOVUDINE | PharmaCare | N-022018 DISCN | 2017-03-17 | 1 products |
COMBIVIR | ViiV Healthcare | N-020857 DISCN | 1997-09-26 | 1 products, RLD |
Brand Name | Status | Last Update |
---|---|---|
abacavir and lamivudine | ANDA | 2023-10-30 |
abacavir sulfate, lamivudine and zidovudine | ANDA | 2016-05-04 |
abacavir, lamivudine and zidovudine | ANDA | 2023-10-31 |
delstrigo | New Drug Application | 2023-11-14 |
dovato | New Drug Application | 2023-11-03 |
efavirenz, lamivudine and tenofovir disoproxil fumarate | ANDA | 2023-11-15 |
epzicom | New Drug Application | 2022-12-14 |
symfi | New Drug Application | 2019-09-09 |
symfi lo | New Drug Application | 2019-10-15 |
triumeq | New Drug Application | 2021-03-23 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
acquired immunodeficiency syndrome | EFO_0000765 | D000163 | B20 |
hepatitis b | — | D006509 | — |
hiv infections | EFO_0000764 | D015658 | B20 |
Expiration | Code | ||
---|---|---|---|
ABACAVIR SULFATE / DOLUTEGRAVIR SODIUM / LAMIVUDINE, TRIUMEQ, VIIV HLTHCARE | |||
2026-12-15 | PED | ||
2026-06-15 | M-294 | ||
ABACAVIR SULFATE / DOLUTEGRAVIR SODIUM / LAMIVUDINE, TRIUMEQ PD, VIIV HLTHCARE | |||
2026-12-15 | PED | ||
2026-06-15 | NPP | ||
DORAVIRINE / LAMIVUDINE / TENOFOVIR DISOPROXIL FUMARATE, DELSTRIGO, MSD MERCK CO | |||
2025-01-27 | NPP |
Patent | Expires | Flag | FDA Information |
---|---|---|---|
Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate, Delstrigo, Msd Merck Co | |||
10603282 | 2036-11-29 | DP | |
10842751 | 2036-11-29 | DP | |
8486975 | 2031-10-07 | DS, DP | U-2395, U-2629, U-3307 |
Dolutegravir Sodium / Lamivudine, Dovato, Viiv Hlthcare | |||
11234985 | 2031-01-24 | DP | U-257 |
Abacavir Sulfate / Dolutegravir Sodium / Lamivudine, Triumeq, Viiv Hlthcare | |||
9242986 | 2029-12-08 | DS, DP | |
8129385 | 2027-10-05 | DS, DP | |
Lamivudine / Raltegravir Potassium, Dutrebis, Merck Sharp Dohme | |||
7754731 | 2029-03-11 | DS, DP | U-1663 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hiv infections | D015658 | EFO_0000764 | B20 | 38 | 111 | 143 | 101 | 83 | 458 |
Hiv | D006678 | — | O98.7 | 12 | 17 | 20 | 38 | 13 | 90 |
Chronic hepatitis b | D019694 | EFO_0004239 | B18.1 | 2 | 11 | 16 | 34 | 14 | 76 |
Infections | D007239 | EFO_0000544 | — | 7 | 5 | 15 | 5 | 5 | 37 |
Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | 2 | 5 | 12 | 10 | 2 | 29 |
Hepatitis b | D006509 | — | — | — | 6 | 9 | 5 | 8 | 27 |
Tuberculosis | D014376 | EFO_0000774 | A15-A19 | 4 | 6 | 6 | 4 | 3 | 21 |
Hiv-1 | D015497 | — | — | — | 4 | 3 | 4 | — | 11 |
Hepatocellular carcinoma | D006528 | — | C22.0 | — | — | 1 | 3 | 3 | 7 |
Cardiovascular diseases | D002318 | HP_0001626 | — | — | 1 | — | 3 | 2 | 6 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Pregnancy | D011247 | EFO_0002950 | Z33.1 | 5 | 2 | 4 | — | — | 9 |
Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | 1 | 1 | 2 | — | 4 | 7 |
Hiv seropositivity | D006679 | — | — | — | 1 | 2 | — | — | 3 |
Malaria | D008288 | EFO_0001068 | B54 | 1 | — | 2 | — | — | 3 |
Liver transplantation | D016031 | EFO_0010682 | — | — | — | 1 | — | 2 | 3 |
Lymphoma | D008223 | — | C85.9 | 1 | 3 | 1 | — | — | 3 |
Chronic hepatitis c | D019698 | EFO_0004220 | B18.2 | — | — | 1 | — | 1 | 2 |
Hiv-2 | D015498 | — | — | — | — | 2 | — | — | 2 |
Neoplasms | D009369 | — | C80 | — | — | 1 | — | 1 | 2 |
Liver diseases | D008107 | HP_0002910 | K70-K77 | 1 | 1 | 1 | — | — | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Pulmonary tuberculosis | D014397 | EFO_1000049 | A15 | 1 | 1 | — | — | — | 2 |
Non-hodgkin lymphoma | D008228 | — | C85.9 | — | 2 | — | — | — | 2 |
Liver failure | D017093 | HP_0001399 | K72.9 | 1 | 1 | — | — | 1 | 2 |
Respiratory tract infections | D012141 | — | J06.9 | 1 | 1 | — | — | — | 1 |
Htlv-ii infections | D015491 | EFO_1001349 | — | — | 1 | — | — | — | 1 |
Metabolic bone diseases | D001851 | HP_0000938 | — | — | 1 | — | — | — | 1 |
Alzheimer disease | D000544 | EFO_0000249 | F03 | 1 | 1 | — | — | — | 1 |
Colorectal neoplasms | D015179 | — | — | — | 1 | — | — | — | 1 |
Glomerulonephritis | D005921 | HP_0000099 | N05 | — | 1 | — | — | — | 1 |
Chronic hepatitis d | D019701 | — | — | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | — | — | 4 | — | — | — | — | 4 |
Gender dysphoria | D000068116 | — | F64 | 1 | — | — | — | — | 1 |
Medication adherence | D055118 | EFO_0006344 | — | 1 | — | — | — | — | 1 |
Aids dementia complex | D015526 | EFO_0002608 | — | 1 | — | — | — | — | 1 |
Lung diseases | D008171 | HP_0002088 | J98.4 | 1 | — | — | — | — | 1 |
Multidrug-resistant tuberculosis | D018088 | EFO_0007381 | — | 1 | — | — | — | — | 1 |
Retinal detachment | D012163 | EFO_0005773 | H33.2 | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Portal hypertension | D006975 | EFO_0000666 | K76.6 | — | — | — | — | 2 | 2 |
Bone density | D015519 | EFO_0003923 | M85 | — | — | — | — | 1 | 1 |
Meningeal tuberculosis | D014390 | — | A17.0 | — | — | — | — | 1 | 1 |
Sustained virologic response | D000072230 | — | — | — | — | — | — | 1 | 1 |
Acute liver failure | D017114 | HP_0004448 | — | — | — | — | — | 1 | 1 |
Patient preference | D057240 | — | — | — | — | — | — | 1 | 1 |
Inferior wall myocardial infarction | D056989 | EFO_1000983 | — | — | — | — | — | 1 | 1 |
B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | — | — | — | — | 1 | 1 |
Malnutrition | D044342 | EFO_0008572 | E40-E46 | — | — | — | — | 1 | 1 |
Protein-energy malnutrition | D011502 | EFO_0009563 | E41 | — | — | — | — | 1 | 1 |
Drug common name | Lamivudine |
INN | lamivudine |
Description | Lamivudine is a monothioacetal that consists of cytosine having a (2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl moiety attached at position 1. An inhibitor of HIV-1 reverse transcriptase, it is used as an antiviral in the treatment of AIDS and hepatitis B. It has a role as a HIV-1 reverse transcriptase inhibitor, an antiviral drug, an anti-HBV agent, an allergen, a prodrug and an EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor. It is a monothioacetal, a primary alcohol, an oxacycle and a nucleoside analogue. It is functionally related to a cytosine. |
Classification | Small molecule |
Drug class | antineoplastics; antivirals (zidovudine group) (exception: edoxudine) |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | Nc1ccn([C@@H]2CS[C@H](CO)O2)c(=O)n1 |
PDB | — |
CAS-ID | 134678-17-4 |
RxCUI | — |
ChEMBL ID | CHEMBL141 |
ChEBI ID | 63577 |
PubChem CID | 60825 |
DrugBank | DB00709 |
UNII ID | 2T8Q726O95 (ChemIDplus, GSRS) |